Obesity and cancer: focus on leptin

Mol Biol Rep. 2023 Jul;50(7):6177-6189. doi: 10.1007/s11033-023-08525-y. Epub 2023 May 25.

Abstract

Over the past decades, obesity has grown to epidemic proportions worldwide. It has been associated with an increased risk for different types of cancer. In addition, obesity has been associated with a poor prognosis, an increased risk of metastasis and mortality, and resistance to anti-cancer therapies. The pathophysiological mechanisms underlying the obesity-cancer connection have not yet been fully elucidated. However, this connection could result, at least in part, from the action of adipokines, whose levels are increased in obesity. Among these adipokines, evidence suggests leptin's critical role in linking obesity to cancer. In this review, we first summarize the current state of the literature regarding the implication of leptin in tumorigenic processes. Next, we focus on the effects of leptin on the anti-tumor immune response. Then, we discuss the influence of leptin on the efficiency of antineoplastic treatments and the development of tumor resistance. Finally, we highlight the use of leptin as a potential target for the prevention and treatment of cancer.

Keywords: Adipokine; Cancer; Leptin; Obesity.

Publication types

  • Review

MeSH terms

  • Adipokines
  • Antineoplastic Agents* / pharmacology
  • Humans
  • Leptin / pharmacology
  • Neoplasms* / complications
  • Obesity / pathology

Substances

  • Adipokines
  • Antineoplastic Agents
  • Leptin
  • LEP protein, human